# Serina Therapeutics, Inc.: financial statements, quarterly

SER · NYSE · CIK 1708599 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ser.md) · [Financials](/companies/ser/financials.md) · [Filings](/companies/ser/filings.md) · [Insiders](/companies/ser/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ser/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001708599-24-000026.md) | [3.1 d](/filings/0001708599-25-000027.md) | [0.0](/filings/0001708599-25-000053.md) | [0.1](/filings/0001708599-25-000089.md) | [0.0](/filings/0001708599-25-000133.md) | [(0.0) d](/filings/0001708599-26-000016.md) | [0.0](/filings/0001708599-25-000053.md) | [0.1](/filings/0001708599-26-000047.md) | [0.0](/filings/0001708599-25-000133.md) | [0.0 d](/filings/0001708599-26-000016.md) | not reported | [0.0](/filings/0001708599-26-000047.md) |
| Cost of revenue | $m | [0.0](/filings/0001493152-23-041126.md) | [0.0 d](/filings/0001493152-24-011022.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [0.0](/filings/0001493152-23-041126.md) | [0.1 d](/filings/0001493152-24-011022.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [0.6](/filings/0001708599-24-000026.md) | [0.9 d](/filings/0001708599-25-000027.md) | [1.1](/filings/0001708599-25-000053.md) | [1.6](/filings/0001708599-25-000089.md) | [2.4](/filings/0001708599-25-000133.md) | [2.4 d](/filings/0001708599-26-000016.md) | [3.0](/filings/0001708599-26-000035.md) | [3.2](/filings/0001708599-26-000047.md) | [3.7](/filings/0001708599-25-000133.md) | [3.4 d](/filings/0001708599-26-000016.md) | [3.2](/filings/0001708599-26-000035.md) | [3.8](/filings/0001708599-26-000047.md) |
| Operating income | $m | [(1.5)](/filings/0001708599-24-000026.md) | [0.2 d](/filings/0001708599-25-000027.md) | [(2.3)](/filings/0001708599-25-000053.md) | [(3.9)](/filings/0001708599-25-000089.md) | [(5.3)](/filings/0001708599-25-000133.md) | [(5.5) d](/filings/0001708599-26-000016.md) | [(5.9)](/filings/0001708599-25-000053.md) | [(5.6)](/filings/0001708599-26-000047.md) | [(6.4)](/filings/0001708599-25-000133.md) | [(6.2) d](/filings/0001708599-26-000016.md) | not reported | [(6.8)](/filings/0001708599-26-000047.md) |
| Interest expense | $m | [3.0](/filings/0001493152-23-041126.md) | [(0.0) d](/filings/0001493152-24-011022.md) | [0.1](/filings/0001493152-24-019248.md) | [0.3](/filings/0001708599-25-000089.md) | [0.0](/filings/0001708599-25-000133.md) | [0.0 d](/filings/0001708599-26-000016.md) | [0.0](/filings/0001708599-26-000035.md) | [0.0](/filings/0001708599-26-000047.md) | [0.0](/filings/0001708599-25-000133.md) | [0.2 d](/filings/0001708599-26-000016.md) | [0.2](/filings/0001708599-26-000035.md) | [0.2](/filings/0001708599-26-000047.md) |
| Income tax | $m | [0.0](/filings/0001493152-23-041126.md) | [0.0 d](/filings/0001708599-25-000027.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001708599-26-000035.md) | not reported | not reported | not reported | [0.0](/filings/0001708599-26-000035.md) | not reported |
| Net income | $m | [1.8](/filings/0001708599-24-000026.md) | [1.1 d](/filings/0001708599-25-000027.md) | [(15.0)](/filings/0001708599-25-000053.md) | [5.2](/filings/0001708599-25-000089.md) | [1.4](/filings/0001708599-25-000133.md) | [(2.7) d](/filings/0001708599-26-000016.md) | [(4.8)](/filings/0001708599-26-000035.md) | [(6.4)](/filings/0001708599-26-000047.md) | [(4.6)](/filings/0001708599-25-000133.md) | [(3.3) d](/filings/0001708599-26-000016.md) | [(6.9)](/filings/0001708599-26-000035.md) | [(6.4)](/filings/0001708599-26-000047.md) |
| Diluted EPS | $ per share | [0.23](/filings/0001708599-24-000026.md) | not reported | [(5.38)](/filings/0001708599-25-000053.md) | [0.51](/filings/0001708599-25-000089.md) | [0.13](/filings/0001708599-25-000133.md) | not reported | [(0.49)](/filings/0001708599-26-000035.md) | [(0.66)](/filings/0001708599-26-000047.md) | [(0.45)](/filings/0001708599-25-000133.md) | not reported | [(0.58)](/filings/0001708599-26-000035.md) | [(0.55)](/filings/0001708599-26-000047.md) |
| Basic EPS | $ per share | [0.80](/filings/0001708599-24-000026.md) | not reported | [(5.38)](/filings/0001708599-25-000053.md) | [0.61](/filings/0001708599-25-000089.md) | [0.16](/filings/0001708599-25-000133.md) | not reported | [(0.49)](/filings/0001708599-26-000035.md) | [(0.66)](/filings/0001708599-26-000047.md) | [(0.45)](/filings/0001708599-25-000133.md) | not reported | [(0.58)](/filings/0001708599-26-000035.md) | [(0.55)](/filings/0001708599-26-000047.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.4](/filings/0001493152-23-041126.md) | [7.6](/filings/0001708599-25-000027.md) | [8.7](/filings/0001493152-24-019248.md) | [6.1](/filings/0001493152-24-030988.md) | [3.2](/filings/0001708599-24-000026.md) | [3.7](/filings/0001708599-26-000016.md) | [4.3](/filings/0001708599-25-000053.md) | [6.0](/filings/0001708599-25-000089.md) | [8.6](/filings/0001708599-25-000133.md) | [3.1](/filings/0001708599-26-000047.md) | [24.5](/filings/0001708599-26-000035.md) | [23.0](/filings/0001708599-26-000047.md) |
| Current assets | $m | [1.1](/filings/0001493152-23-041126.md) | [7.6](/filings/0001708599-25-000027.md) | [8.9](/filings/0001493152-24-019248.md) | [8.9](/filings/0001493152-24-030988.md) | [5.4](/filings/0001708599-24-000026.md) | [5.7](/filings/0001708599-26-000016.md) | [5.8](/filings/0001708599-25-000053.md) | [8.0](/filings/0001708599-25-000089.md) | [11.5](/filings/0001708599-25-000133.md) | [6.1](/filings/0001708599-26-000047.md) | [26.5](/filings/0001708599-26-000035.md) | [25.0](/filings/0001708599-26-000047.md) |
| Total assets | $m | [12.2](/filings/0001493152-23-041126.md) | [9.0](/filings/0001708599-25-000027.md) | [10.9](/filings/0001493152-24-019248.md) | [10.7](/filings/0001493152-24-030988.md) | [7.4](/filings/0001708599-24-000026.md) | [6.7](/filings/0001708599-26-000016.md) | [6.7](/filings/0001708599-25-000053.md) | [8.9](/filings/0001708599-25-000089.md) | [12.4](/filings/0001708599-25-000133.md) | [7.0](/filings/0001708599-26-000047.md) | [27.3](/filings/0001708599-26-000035.md) | [25.8](/filings/0001708599-26-000047.md) |
| Current liabilities | $m | [3.2](/filings/0001493152-23-041126.md) | [1.4](/filings/0001708599-25-000027.md) | [14.1](/filings/0001493152-24-019248.md) | [12.6](/filings/0001493152-24-030988.md) | [13.5](/filings/0001708599-24-000026.md) | [2.4](/filings/0001708599-26-000016.md) | [2.4](/filings/0001708599-25-000053.md) | [3.6](/filings/0001708599-25-000089.md) | [8.8](/filings/0001708599-25-000133.md) | [3.6](/filings/0001708599-26-000047.md) | [6.3](/filings/0001708599-26-000035.md) | [3.8](/filings/0001708599-26-000047.md) |
| Total liabilities | $m | [3.9](/filings/0001493152-23-041126.md) | [4.9](/filings/0001708599-25-000027.md) | [15.2](/filings/0001493152-24-019248.md) | [27.1](/filings/0001493152-24-030988.md) | [21.3](/filings/0001708599-24-000026.md) | [6.2](/filings/0001708599-26-000016.md) | [5.2](/filings/0001708599-25-000053.md) | [7.3](/filings/0001708599-25-000089.md) | [10.8](/filings/0001708599-25-000133.md) | [7.0](/filings/0001708599-26-000047.md) | [9.7](/filings/0001708599-26-000035.md) | [7.1](/filings/0001708599-26-000047.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | [11.2](/filings/0001708599-24-000026.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(27.5)](/filings/0001493152-23-041126.md) | [(32.3)](/filings/0001708599-25-000027.md) | [(4.3)](/filings/0001493152-24-019248.md) | [(16.4)](/filings/0001493152-24-030988.md) | [(13.8)](/filings/0001708599-24-000026.md) | [0.6](/filings/0001708599-26-000016.md) | [1.7](/filings/0001708599-25-000053.md) | [1.8](/filings/0001708599-25-000089.md) | [1.8](/filings/0001708599-25-000133.md) | [(0.0)](/filings/0001708599-26-000016.md) | [17.6](/filings/0001708599-26-000047.md) | [18.7](/filings/0001708599-26-000047.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,024) d](/filings/0001708599-24-000026.md) | [121 d](/filings/0001708599-25-000027.md) | [(1,577)](/filings/0001708599-25-000053.md) | [(8,009) d](/filings/0001708599-25-000089.md) | [(2,962) d](/filings/0001708599-25-000133.md) | [(4,589) d](/filings/0001708599-26-000016.md) | [(4,322)](/filings/0001708599-26-000035.md) | [(3,750) d](/filings/0001708599-26-000047.md) | [(3,850) d](/filings/0001708599-25-000133.md) | [(6,033) d](/filings/0001708599-26-000016.md) | [(4,568)](/filings/0001708599-26-000035.md) | [(6,684) d](/filings/0001708599-26-000047.md) |
| Capital expenditure | $k | [119 d](/filings/0001708599-24-000026.md) | [70.0 d](/filings/0001708599-25-000027.md) | [14.0](/filings/0001708599-25-000053.md) | [0.0 d](/filings/0001708599-25-000089.md) | [3.0 d](/filings/0001708599-25-000133.md) | [5.0 d](/filings/0001708599-26-000016.md) | [0.0](/filings/0001708599-26-000035.md) | [46.0 d](/filings/0001708599-26-000047.md) | [13.0 d](/filings/0001708599-25-000133.md) | [0.0 d](/filings/0001708599-26-000016.md) | [25.0](/filings/0001708599-26-000035.md) | [28.0 d](/filings/0001708599-26-000047.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0001493152-23-041126.md) | [8.6](/filings/0001493152-24-019248.md) | [0.0](/filings/0001493152-24-030988.md) | [7.6](/filings/0001708599-24-000026.md) | [2.8](/filings/0001708599-25-000053.md) | [10.2](/filings/0001708599-25-000089.md) | [10.8](/filings/0001708599-25-000133.md) | [9.8](/filings/0001708599-26-000035.md) | [10.0](/filings/0001708599-26-000047.md) | [10.3](/filings/0001708599-25-000133.md) | [12.0](/filings/0001708599-26-000035.md) | [16.4](/filings/0001708599-26-000047.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 25,400,473 at 2026-08-10, from the cover of the [10-Q filed 2026-08-13](/filings/0001708599-26-000047.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.